AHA Guidelines: ICD Indications in HCM

ICD Indications in Hypertrophic Cardiomyopathy (HCM)

Hypertrophic cardiomyopathy (HCM) is one of the most common inherited cardiac disorders and an important cause of sudden cardiac death (SCD), particularly in young individuals and athletes. Implantable cardioverter-defibrillator (ICD) therapy is the most effective strategy for preventing SCD in these patients. Current recommendations are mainly derived from the American Heart Association and American College of Cardiology guidelines.

---

Purpose of ICD in HCM

The primary role of an ICD in HCM is prevention of sudden cardiac death due to malignant ventricular arrhythmias such as ventricular tachycardia or ventricular fibrillation.

ICD therapy is used in two situations:

• Secondary prevention

• Primary prevention (based on risk stratification)

---

1. Secondary Prevention ICD

ICD implantation is strongly recommended (Class I indication) in HCM patients with any of the following:

• Prior cardiac arrest due to ventricular fibrillation

• Sustained ventricular tachycardia causing hemodynamic instability

• Documented spontaneous sustained VT

These patients have a very high risk of recurrent malignant arrhythmias, and ICD therapy significantly reduces mortality.

---

2. Primary Prevention ICD

Primary prevention focuses on identifying patients at high risk of sudden cardiac death.

According to the American Heart Association / American College of Cardiology 2020 guidelines, ICD implantation is reasonable (Class IIa) when one or more major risk markers are present.

Major Risk Factors for SCD in HCM

1. Massive LV Hypertrophy

Maximum LV wall thickness ≥ 30 mm on echocardiography or cardiac MRI.

2. Family History of SCD

Sudden cardiac death in a first-degree relative due to HCM, especially before age 50.

3. Unexplained Syncope

Recent unexplained syncope suspected to be arrhythmic.

4. LV Apical Aneurysm

Presence of a left ventricular apical aneurysm detected on imaging.

5. LV Systolic Dysfunction

Left ventricular ejection fraction ≤ 50%.

6. Extensive Late Gadolinium Enhancement

Extensive myocardial fibrosis on cardiac MRI (>15% LV mass).

---

Additional Risk Modifiers

These factors may support ICD decision-making but are not standalone indications:

• Non-sustained ventricular tachycardia on Holter monitoring

• Abnormal blood pressure response to exercise

• Severe left atrial enlargement

• LV outflow tract obstruction

• High risk score on the HCM Risk‑SCD Score

---

ESC Risk Calculator Approach

The European Society of Cardiology recommends using the HCM Risk-SCD calculator to estimate 5-year risk of sudden cardiac death.

Risk-Based Recommendations

• ≥ 6% risk → ICD recommended

• 4–6% risk → ICD should be considered

• < 4% risk → ICD usually not recommended

Variables used in the risk model include:

• Age

• Maximum LV wall thickness

• Left atrial diameter

• LVOT gradient

• Family history of SCD

• Non-sustained VT

• Unexplained syncope

---

Special Situations

Pediatric HCM

Risk stratification differs slightly and often includes:

• Extreme hypertrophy

• Unexplained syncope

• NSVT

• Family history of SCD

Athletes

HCM remains a major cause of sudden death in athletes, and ICD may be recommended even with borderline risk profiles.

---

Complications of ICD in HCM

Although life-saving, ICD therapy has potential complications:

• Inappropriate shocks

• Lead failure

• Infection

• Psychological impact

• Device replacement in young patients

Therefore, careful risk-benefit assessment and shared decision-making are essential.

---

Key Takeaway

ICD implantation is the most effective strategy for preventing sudden cardiac death in hypertrophic cardiomyopathy. Secondary prevention indications are clear, while primary prevention requires careful evaluation of major risk markers such as massive hypertrophy, family history of SCD, syncope, LV dysfunction, and apical aneurysm.